News | July 10, 2013

Study Demonstrates Improved Monitoring of Patients at Risk for Cardiotoxicity Using EchoInsight for Cardio Oncology

Results indicate EchoInsight for Cardio Oncology is a high quality, efficient application for comprehensive assessment and serial comparison of left ventricle (LV) function

EchoInsight for Cardio Oncology Clinical Study Left Ventricle Function

July 10, 2013 — Epsilon Imaging Inc. announced a clinical study demonstrating EchoInsight for Cardio Oncology to be a high quality, efficient application for comprehensive assessment of left ventricle (LV) function. The study, presented at the ASE 2013 Scientific Sessions in Minneapolis, Minn., further indicated EchoInsight for Cardio Oncology facilitates monitoring of patients at risk for cardiotoxicity. EchoInsight for Cardio Oncology is a vendor neutral application designed to assist clinicians in improving confidence and workflow of study interpretation and reporting when monitoring oncology patients.

At ASE 2013, Jeanne DeCara, M.D., et al. from the University of Chicago Medicine presented, “Vendor Independent Software for Rapid Comprehensive Assessment of Changes in Left Ventricle Function During Serial Echocardiographic Studies.” The study analyzed serial comparison studies from 30 subjects. Ejection fraction (EF) and longitudinal strain were measured to monitor change in cardiac function. An experienced reader reviewed the studies on another commercially available solution, and an inexperienced reader used EchoInsight for Cardio Oncology for analysis. The inexperienced reader also completed analysis without EchoInsight for Cardio Oncology. Study results concluded that analysis and interpretation is faster using EchoInsight for Cardio Oncology when compared to the other commercial application, and offers consistent findings. EchoInsight for Cardio Oncology also slightly improved the inexperienced reader’s assessment of LV function change.

“Our study demonstrates EchoInsight for Cardio Oncology offers visualization and analysis that allows for quick, easy and accurate interpretation of LV function over time,” said DeCara. “EchoInsight is a promising software application that may assist in the follow-up of patients undergoing potentially cardiotoxic treatments, such as chemotherapy.”

For more information: www.epsilon-imaging.com


Related Content

News | Cardiac Imaging

Nov. 13, 2024 – A recent study has demonstrated the value of the single-exposure dual-energy X-ray detector in advancing ...

Home November 13, 2024
Home
News | Cardiac Imaging

Oct. 15, 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage ...

Home October 16, 2024
Home
News | Cardiac Imaging

Oct. 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend ...

Home October 15, 2024
Home
News | Cardiac Imaging

PHOTO CAPTION: The Elucid PlaqueIQ user interface is a fully interactive visualization of the patient’s coronary anatomy ...

Home October 01, 2024
Home
News | Cardiac Imaging

Aug. 21, 2024 — NANO-X IMAGING LTD recently announced that its deep-learning medical imaging analytics subsidiary, Nanox ...

Home August 22, 2024
Home
News | Cardiac Imaging

July 23, 2024 — EMVision, an Australian medical device company focused on the development and commercialization of ...

Home July 23, 2024
Home
News | Cardiac Imaging

July 12, 2024 — Researchers have developed a groundbreaking method for analyzing heart MRI scans with the help of ...

Home July 12, 2024
Home
News | Cardiac Imaging

June 10, 2024 — New expert consensus from the Society of Cardiovascular Computed Tomography (SCCT) reviews previously ...

Home June 10, 2024
Home
News | Cardiac Imaging

May 10, 2024 — According to the Summa Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual ...

Home May 10, 2024
Home
News | Cardiac Imaging

April 29, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Home April 29, 2024
Home
Subscribe Now